Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
NCT05986240Phase 1Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of danvatirsen in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Overall Response Rate at 14 weeks. Started May 2024; status: recruiting.
02
Drugs
danvatirsen
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05986240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986240.